Abstract
目的 观察国产甲磺酸伊马替尼治疗初诊慢性粒细胞白血病慢性期(CML-CP)的效果及安全性。 方法 回顾性分析东莞市人民医院2014年10月至2016年10月收治的23例年龄>18岁、初次确诊、除羟基脲外未接受其他任何抗CML治疗的CML-CP患者临床资料,所有患者均接受国产甲磺酸伊马替尼400 mg/次,1次/d口服治疗,评价3、6、12个月时的血液学、分子生物学反应及安全性。 结果 23例患者治疗后均达到血液学完全缓解。在可评估的20例患者中,在3个月时15例bcr-abl国际标准化(IS)值<10%;治疗6个月时16例达bcr-abl<1%;治疗12个月时8例bcr-abl<0.1%。不良反应均可耐受。 结论 国产甲磺酸伊马替尼治疗初诊CML-CP疗效可靠,不良反应可耐受。
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.